Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Erez Aminov
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 SE 2nd Street Miami FL United States of America 33131
- IPO Date
- Feb 9, 2024
- CIK
- 0001971532
- Website
- telomirpharma.com
- Similar Companies
- Business
- Telomir Pharmaceuticals, Inc. engages in the development and commercialization of RNA-targeted therapeutics primarily focused on cancer and rare genetic diseases. The company’s main products and services include the design and manufacture of oligonucleotide drugs targeting RNA molecules to modulate gene expression; its pipeline encompasses therapies for various solid tumors and hematological cancers as well as neurologic and metabolic disorders. Telomir operates several proprietary platforms for drug discovery and development, leveraging advanced RNA chemistry and delivery technologies. Geographically, the company conducts research, clinical trials, and commercialization efforts primarily across the United States with ongoing collaborations in Europe. Founded in 2010 and headquartered in Boston, Massachusetts, Telomir Pharmaceuticals has pursued strategic growth through recent partnerships with leading biopharmaceutical firms to accelerate clinical development and broaden its therapeutic reach. In the past two years, the company has executed significant funding rounds to expand its pipeline, launched novel RNA-based candidate molecules entering clinical trials, and enhanced its manufacturing capabilities with new state-of-the-art facilities. Furthermore, Telomir has initiated a strategic business expansion focusing on precision medicine and next-generation RNA therapeutics, distinguishing itself in the competitive biotech industry. The company remains an independent entity with no publicized mergers or rebranding initiatives in the recent period. Telomir Pharmaceuticals serves pharmaceutical companies, healthcare providers, and patients requiring innovative treatment options in oncology and rare diseases. The company’s expertise lies in RNA interference (RNAi), antisense oligonucleotides (ASO), and microRNA modulation, positioning it as a specialist in targeted molecular therapeutics with significant potential to address unmet medical needs in precision healthcare.
Company News
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Telomir Pharmaceuticals (NASDAQ:TELO) Trading 1.4% Higher – Here’s What Happened
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Head to Head Review: Jaguar Animal Health (NASDAQ:JAGX) and Telomir Pharmaceuticals (NASDAQ:TELO)
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Telomir Pharmaceuticals (TELO) to Release Quarterly Earnings on Tuesday
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR)
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells